Patent intelligence · US
US 12145963
Phenothiazine derivatives and uses thereof
Phenothiazine derivatives and uses thereof
Patent details — US 12145963
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 19, 2024
- Expiration
- Nov 14, 2044
- Applicant
- CAMP4 Therapeutics Corporation
- Claims
- 1
- CPC classes
- A61P, A61P1/00, A61P1/12, A61P25/28
Quick answer
US 12145963 (Phenothiazine derivatives and uses thereof) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAMP4 Therapeutics Corporation
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61P, A61P1/00, A61P1/12, A61P25/28, A61P43/00, A61P7/06
More from CAMP4 Therapeutics Corporation
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12145963?
US 12145963 (Phenothiazine derivatives and uses thereof) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12145963?
CAMP4 Therapeutics Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12145963 expire?
Our index shows an expiration date of Nov 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.